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Abstract  Lung  cancer  (LC)  is  a  major  public  health  issue  because  of  its  frequency,  but  espe-
cially because  of  the  severity  of  this  disease.  The  epidemiology  has  changed  with  an  increased
incidence  in  non-smokers  and  women.  The  ATS/ERS/IASLC  classiﬁcation  of  adenocarcinomas
was modiﬁed  in  2011,  and  they  are  now  the  most  frequent  histological  subtype.  More  than  half
the cases  of  LC  are  diagnosed  at  the  metastatic  stage.  Biopsies  must  provide  tissue  samples
that are  quantitatively  large  enough  and  of  a  good  enough  quality  for  diagnosis  and  to  search
for biomarkers.  When  the  cancer  seems  to  be  localized,  precise  staging  must  be  obtained.
Treatment  is  based  on  the  TNM  classiﬁcation.  In  localized  stages,  lobectomy  associated  with
lymph node  dissection  is  the  standard  therapy.  Intraoperative  chemotherapy  improves  survival
in case  of  lymph  node  inﬁltration.  Stereotactic  radiation  therapy  and  radiofrequency  can  be
considered  as  speciﬁc  cases.  In  cases  with  local  progression,  treatment  is  more  controversial.
In the  presence  of  metastases,  the  goal  is  not  a  cure,  but  improving  survival  and  quality  of  life.
Numerous  advances  have  been  made  with  personalized  treatment,  (in  particular  in  relation  to
the histological  type  and  oncogenic  addiction  in  tumors,  access  to  new  drugs,  and  improved
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management).  Clinical  research  in  thoracic  cancer  is  very  active.  The  ﬁght  against  tobacco
should remain  a  priority.
©  2014  Éditions  franc¸aises  de  radiologie.  Published  by  Elsevier  Masson  SAS.  All  rights  reserved.
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fpidemiology of non-small cell lung
arcinoma (NSCLC)
ith  39,495  cases  diagnosed  in  2012  in  France  and  29,949
eaths  [1],  lung  cancer  (LC)  remains  a  major  public  health
roblem  because  of  its  frequency,  but  especially  the  sever-
ty  of  the  disease.  LC  is  the  cause  of  the  greatest  number
f  cancer  deaths  per  year  in  France  (20%)  [1].  While  mor-
ality  from  this  disease  is  decreasing  in  men,  it  continues
o  increase  in  women  [2].  In  the  last  ten  years,  the  epi-
emiology  has  changed  [3].  The  incidence  of  this  disease
s  increasing  in  non-smokers  (11%  of  LC  in  France)  and  in
omen.  Ten  years  ago  squamous  cell  carcinoma  was  more
requent  than  adenocarcinoma  (39%  vs  29%).  Today,  the  dis-
ribution  has  changed  with  46%  of  adenocarcinomas,  26%
quamous  cell  carcinomas  10%  large  cell  carcinomas  and  13%
mall  cell  carcinomas.  The  ATS/ERS/IASLC  classiﬁcation  of
denocarcinomas  was  modiﬁed  in  2011  [4],  and  now  includes
our  new  entities:  adenocarcinoma  in  situ,  minimally  inva-
ive  adenocarcinoma,  lepidic  predominant  non-mucinous
denocarcinoma,  and  invasive  mucinous  adenocarcinoma.
ecause  of  the  strong  anatomoradiological  correlation,  this
ew  classiﬁcation  also  has  implications  for  the  radiologist
5].  This  classiﬁcation,  which  was  developed  for  biopsy  sam-
les,  has  been  adapted  to  small  tissue  specimens  [6].
ytological and biopsy tissue specimens
or  diagnosis
ore  than  half  LC  is  diagnosed  at  the  metastatic  stage  [3].
n  this  case,  the  physician  performing  the  biopsy,  whether
/he  is  an  endoscopist  or  a  radiologist,  s/he  must  obtain
pecimens  that  are  quantitatively  large  enough  and  qual-
tatively  good  enough  to  obtain  a  precise  diagnosis  and
dentify  biomarkers  to  help  determine  the  treatment  strat-
gy.  Today,  the  histological  type  and  the  molecular  proﬁle
re  determining  factors  of  the  therapeutic  strategy.  The
ASLC  recommends  searching  for  an  EGFR  mutation  and
n  ALK  translocation  [7]  in  all  metastatic  adenocarcino-
as,  whatever  the  clinical  features,  because  there  are
argeted  therapies  for  these  two  molecular  anomalies  that
ave  obtained  French  marketing  (AMM)  approval.  Since
006,  INCa  has  organized  molecular  genetics  platforms  to
etermine  molecular  proﬁle  of  tumors  and  identify  new
herapeutic  targets  to  help  develop  targeted  treatments  and
ake  personalized  medicine  a  reality  for  patients.  Biomar-
ueurs  France  is  a  database  that  includes  all  molecular
nalyses  performed  in  INCa  approved  platforms  since  2012.
n  one  year,  10,000  LC  have  been  tested  [8].  It  is  interest-
ng  to  note  that  a  team  from  Grenoble  [9]  has  shown  that
he  reliability  of  transthoracic  needle  biopsies  to  determine
m
s
o
ahe  histological  subtype  and  the  molecular  proﬁle  of  adeno-
arcinomas  has  signiﬁcantly  improved  in  just  two  years
72%  of  the  biopsy  specimens  were  adequate  for  molecu-
ar  analyses  during  the  ﬁrst  period  vs  92  %  during  the  second
eriod).  The  number  as  well  as  the  length  of  the  biopsies  has
ncreased.  Radiologists  have  improved  their  practices  along
ith  pathologists  and  biologists  to  adapt  to  new  guidelines.
ew  techniques,  such  as  radial  probe  endoscopic  ultra-
ound  (EBUS)  have  also  been  developed  in  bronchoscopy  to
mprove  results  [10]  and  electromagnetic  navigation  [11]  has
elped  improve  biopsy  specimens,  especially  of  peripheral
esions.  However,  very  few  centers  have  these  technologies.
nitial evaluation
hen  cancer  seems  to  be  localized,  the  challenges  are
lsewhere.  The  histological  subtype  and  the  molecular
roﬁle  are  not  needed,  because  they  do  not  affect  the
herapeutic  strategy.  On  the  other  hand,  disease  exten-
ion  should  be  precisely  determined.  Contrast-enhanced
horacic  CT  Scan  and  PET  scan  are  recommended  by  the
NCa  [12]  and  the  ACCP  [13].  Brain  imaging  should  be  sys-
ematically  performed  according  to  the  INCa  (CT  scan  or
RI)  and  the  ‘‘guide  to  good  practices  of  imaging  tests’’
gbu.radiologie.fr)  and  is  recommended  in  stage  III  or  IV
isease  by  the  ACCP  (MRI).  To  obtain  reliable  mediasti-
al  staging,  in  the  absence  of  distant  metastases,  imaging
hould  be  associated  with  mini-invasive  procedures  (EBUS,
ndoscopic  ultrasound  (EUS)  or  mediastinoscopy)  in  the
ollowing  cases  [12,13]:  mediastinal  lymph  nodes  ≥  10  mm,
igh  tracer  uptake  on  PET  scan  whatever  the  size  of  the
ymph  node,  the  presence  of  suspicious  hilar  lymph  nodes  or
entral  location  of  the  tumor.  Results  of  EUS  staging  seem  to
e  better  than  mediastinoscopy  [14],  which  is  why  it  is  now
ecommended  as  the  ﬁrst  imaging  test  [13]. The  effective-
ess  of  whole  body  MRI  or  combined  with  PET  scan  is  being
tudied  to  evaluate  disease  extension  in  LC  [15,16].
dvances in treatment strategies
reatment  depends  on  the  TNM  stage.  A  lobectomy  and
ymph  node  dissection  is  the  standard  treatment  for  stages
 and  II.  Video  assisted  surgical  techniques  are  being  devel-
ped.  Infra-lobar  resections,  in  particular  segmentectomies
an  be  discussed  [13]  in  certain  cases:  tumors  less  than
 cm  predominantly  ground  glass  opacity-type,  or  pulmonary
unction  preventing  resection  of  an  entire  lobe.  Approxi-
ately  25%  of  patients  with  local  stage  LC  have  a  major
urgical  contraindication.  Stereotactic  radiotherapy  is  an
ption  if  the  tumor  is  less  than  5  cm  [13]. Radiofrequency  can
lso  be  considered  if  the  tumor  is  less  than  3  cm  but  there
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are  fewer  results  in  the  literature  [13].  Results  of  local  dis-
ease  control  (83—89%  vs  58-68%  at  5  years),  overall  survival
(38—85%  vs  47—74%  at  3  years)  and  the  rate  of  complications
(3—38%  vs  33—100%)  seem  to  be  better  with  stereotactic
radiotherapy  than  with  radiofrequency  [17].  However,  in
the  absence  of  randomized  trials,  these  results  should  be
taken  with  caution.  Two  phase  III  clinical  trials  (ACOSOG
Z4099  and  RTOG  1021  trial)  comparing  partial  resection  to
stereotactic  radiotherapy  in  high  risk  patients  are  ongoing.
The  best  patient  postoperative  follow-up  protocol  must  be
determined.  The  IFCT  phase  III  study  comparing  a  protocol  of
a  clinical  examination  associated  with  thoracic  radiography
to  a  clinical  examination  and  thoracic  and  upper  abdomi-
nal  CT  Scan  and  pulmonary  ﬁbroscopy  in  case  of  a  squamous
cell  tumor,  including  1775  patients  operated  for  LC,  should
provide  a  response.
Platinum-based  adjuvant  chemotherapy  is  indicated  in
stage  II  surgical  patients  [13].  Neoadjuvant  chemotherapy  is
an  option.
Treatment  of  stages  IIIAN2  is  the  subject  of  debate.
The  ACCP  recommends  combined  radiochemotherapy  [13].
Surgery  as  ﬁrst-line  treatment  followed  by  adjuvant
chemotherapy  is  not  recommended  [13].  Chemotherapy  as
ﬁrst-line  treatment  followed  by  surgery  can  be  consid-
ered  if  the  N2  is  small  [13].  Adjuvant  chemotherapy  may
be  indicated  in  patients  with  a  tumor  in  whom  mediasti-
nal  invasion  is  not  known  before  surgery  (cN0  or  N1  and
pN2).  ESMO  [18]  guidelines  are  slightly  different.  If  the
tumor  is  resectable,  radiochemotherapy  and  neoadjuvant
chemotherapy  followed  by  surgery  are  two  options.
Radiochemotherapy  is  indicated  in  stage  IIIB  tumors,  if
the  size  of  the  tumor  permits  curative  radiation.
Treatment  of  stage  IV  tumors  is  supportive,  except  for
rare  cases  of  resectable  pulmonary  tumors  with  pulmonary
(M1a),  adrenal  or  cerebral  metastases  alone.  The  goal  is  not
a  cure  but  to  improve  patient  survival  and  quality  of  life.
The  beneﬁts  of  chemotherapy  are  real  and  the  meta-analysis
published  in  1995  [19]  showed  better  results  with  combi-
nation  platinum  and  a  third  generation  drug  compared  to
supportive  care  alone.  Progress  has  been  made  in  the  last
ten  years.
Today  the  choice  of  chemotherapy  can  be  adapted  to
tumor  histology  (for  example,  by  limiting  pemetrexed  to
non-predominantly  squamous  cell  NSCLC).  Bevacizumab,
the  monoclonal  antibody  acting  on  VEGF,  improves
progression-free  survival  and  probably  overall  survival
[20].  It  can  be  combined  with  chemotherapy  in  case  of
non-squamous  NSCLC.  Indeed,  during  the  development  of
bevacizumab,  cases  of  mortality  from  hemoptysis  were
described  in  phase  II  studies  in  patients  with  squamous  cell
carcinomas,  which  is  why  this  histological  type  has  been
excluded  from  this  option.  Nevertheless,  the  risk  of  hemop-
tysis  persists  and  predictive  radiological  criteria  have  been
developed  [21].  The  evaluation  of  risk  by  a  radiologist  is
therefore  important.
First-line  therapy  includes  4  to  6  cycles  of  chemotherapy.
Before  the  notion  of  maintenance  therapy  was  introduced,
there  was  a  pause  in  treatment  then  second  line  treat-
ment  was  begun  at  tumoral  progression.  Today  this  approach
has  been  validated  because  maintenance  therapy  [22]  has
been  shown  to  improve  progression-free  survival  and  over-
all  survival.  This  may  include  real  maintenance  therapy  or
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ontinuation  maintenance  (the  treatment  used  for  induc-
ion  is  maintained  when  platinum  therapy  is  stopped  until
rogression  or  toxicity)  or  switch  maintenance  (induction
hemotherapy  is  stopped  and  another  type  of  treatment
s  begun).  The  predictive  factors  of  effective  maintenance
herapy  are  still  a  subject  of  debate.  Response  to  induction
herapy  may  play  a  role.  This  hypothesis  is  being  tested  in
rance  in  a  phase  III  trial  (IFCT-GFPC  1101).
New  chemotherapies,  the  association  with  bevacizumab
nd  maintenance  therapy  has  improved  median  progression-
ree  survival  (approximately  7  months)  and  overall  survival
an  reach  up  to  17  months  [23].
Major  progress  has  been  made  in  the  management  of
etastatic  NSCLC  with  the  identiﬁcation  of  oncogenic  addic-
ions  [24]. Tyrosine  kinase  inhibitors  EGFR  (ITK-EGFR)  were
nitially  developed  in  a  non-selected  population.  Clinical
riteria  of  response  to  ITK-EGFR  were  rapidly  identiﬁed
female  gender,  non-smokers,  Asian  and  adenocarcinoma).
GFR  gene  mutations  were  found  to  be  the  best  predic-
ive  factor  of  response  to  treatment.  Today  EGFR  gene
utations  are  systematically  searched  for  in  metastatic
denocarcinomas.  In  the  presence  of  an  activating  muta-
ion  (approximately  10%  of  the  adenocarcinomas  in  France),
he  patient  can  receive  ITK-EGFR  as  ﬁrst-line  therapy.
rogression-free  survival  was  better  than  with  chemother-
py  and  reached  9  months  in  one  Caucasian  population  [25].
he  prognosis  of  patients  with  an  EGFR  mutation  is  better
han  others.  The  median  overall  survival  reached  19  months
n  the  Caucasian  population  [25]. In  the  absence  of  a  muta-
ion,  ITK-EGFR  (only  erlotinib  has  an  AMM  for  this  indication)
an  be  administered  as  a second  line  therapy  or  at  later
ycles.  At  tumoral  progression,  new  tissue  specimens  can
e  obtained  to  determine  the  mechanism  of  resistance
o  ITK  (appearance  of  a  resistance  mutation,  histological
ransformation.  .  .) and  to  adapt  patient  management.  In
007,  the  ALK  translocation  [26]  was  described  in  NSCLC
approximately  4%  of  NSCLC)  and  in  2011,  crizotinib  was
alidated  for  this  indication,  resulting  in  progression-free
urvival  of  between  7  and  9  months.  Other  biomarkers  [24]
ave  been  discovered  including  certain  that  are  associated
ith  targeted  therapies.
Clinical  research  in  immunotherapy  in  NSCLC  seems
romising  [27].  Last  year,  two  phase  I  trials  were  published
n  the  New  England  Journal  of  Medicine,  one  with  anti-PD-1
ntibodies  [28],  the  other  with  an  anti-ligand  antibody  to
D-1  [29].  Although  included  patients  had  received  multi-
le  treatments,  several  of  them  presented  with  objective
esponses.  With  immunotherapy,  the  evaluation  of  response-
o-treatment  can  be  difﬁcult  because  the  immune  cascade
et  off  by  treatment  can  induce  an  initial  increase  in  the
ize  of  targeted  lesions,  or  the  appearance  of  new  lesions.
he  RECIST  criteria  are  not  adapted  which  is  why  speciﬁc
mmunotherapy  criteria  were  published.  [30]. Today  numer-
us  trials  are  underway  in  immunotherapy.
onclusionn  conclusion,  the  management  of  NSCLC  in  particular  at  the
etastatic  stage,  has  changed  signiﬁcantly  in  the  past  few
ears,  both  for  diagnosis  (necessity  of  having  a  large  enough
issue  specimen  to  identify  oncogenic  addictions)  and
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reatment  with  the  availability  of  personalized  medicine.
espite  progress,  the  prognosis  is  still  poor  and  the  ﬁght
gainst  tobacco  as  well  as  diagnostic  campaigns  should  be  a
riority.
TAKE-HOME  MESSAGES
• Biopsy  specimens  should  be  adequate  for  diagnosis
and  the  search  for  biomarkers.
• The  physician  performing  the  biopsy  and  the
pathologist  must  therefore  optimize  their  technique.
• In  localized  stages,  precise  staging  must  be  obtained.
A  lobectomy  associated  with  lymph  node  dissection
is  the  standard  therapy.
• In  metastatic  stages,  treatment  is  determined  by  the
histological  subtype  and  the  presence  of  mutations,
in  particular  EGFR.
• Despite  progress  the  prognosis  is  still  poor.  The  ﬁght
against  tobacco  is  a  priority.
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